Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

NCT02461589 · Completed

Last updated 2026-05-28

This clinical trial tested different doses of the medication semaglutide, given as a daily injection, against a placebo and another diabetes drug called liraglutide in adults with type 2 diabetes to see how it affects their blood sugar levels.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 706 people

Who can join Ages 18+ · all sexes

Timeline Started 2015-09 · est. completion 2016-10

Where 150 sites · Austria, Canada, Czechia, Germany, Malaysia, Russia, Serbia, South Africa, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT02461589 ↗

Description as written by the study sponsor.

This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes

Treatments tested

semaglutide Drug

Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.
liraglutide Drug

Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.
placebo Drug

Administered subcutaneously ( s.c., under the skin) once daily.

Main thing measured	Change in HbA1c (Glycosylated Haemoglobin)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide, liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02461589 ↗